ARIAD Pharmaceuticals (ARIA) has risen sharply, recording gains of 27.13% in the past 4 weeks. However, the stock has corrected -2.55% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 26.64% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
Ariad Pharmaceuticals Inc. is up 33.03% in the last 3-month period. Year-to-Date the stock performance stands at 64.96%. The stock has recorded a 20-day Moving Average of 6.16% and the 50-Day Moving Average is 22.93%.
ARIAD Pharmaceuticals (NASDAQ:ARIA): The stock opened at $10.34 on Friday but the bulls could not build on the opening and the stock topped out at $10.37 for the day. The stock traded down to $10.18 during the day, due to lack of any buying support eventually closed down at $10.31 with a loss of -0.87% for the day. The stock had closed at $10.40 on the previous day. The total traded volume was 2,343,386 shares.
Also, Equity Analysts at the Barclays maintains the rating on ARIAD Pharmaceuticals (NASDAQ:ARIA). The brokerage firm has issued a Underweight rating on the shares. The Analysts at the ratings agency raises the price target from $8 per share to $9 per share. The rating by the firm was issued on July 29, 2016.
ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).